4//SEC Filing
ARCH Venture Partners VIII, L.P. 4
Accession 0001012975-19-000390
CIK 0001661998other
Filed
May 22, 8:00 PM ET
Accepted
May 23, 5:58 PM ET
Size
15.6 KB
Accession
0001012975-19-000390
Insider Transaction Report
Form 4
ARCH Venture Fund VIII, L.P.
10% Owner
Transactions
- Other
Common Stock
2019-05-21−300,001→ 5,768,694 total
Footnotes (3)
- [F1]Distribution of Common Stock held by a limited partnership to its partners for no consideration.
- [F2]Following the transactions reported herein, includes 1,137,663 shares of common stock held of record by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage") and 4,631,031 shares of common stock held of record by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII").
- [F3]The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"). The sole general partner of ARCH Partners VIII and ARCH Fund Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"). ARCH Partners VIII may therefore be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH VIII LLC may be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH Fund Overage. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII and ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Documents
Issuer
Homology Medicines, Inc.
CIK 0001661998
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001616176
Filing Metadata
- Form type
- 4
- Filed
- May 22, 8:00 PM ET
- Accepted
- May 23, 5:58 PM ET
- Size
- 15.6 KB